The results of this study show that increased serum uric acid can accelerate injury in two separate models of PKD and importantly reports fundamental findings in support of the Company's XRx-008 program. Allen Davidoff, CEO of XORTX, stated, "We are pleased to participate in the ASN annual meeting during Kidney Week 2022 with this poster presentation. The aim of this study was to determine whether raising serum uric acid with OXO was associated with worse PKD.ĭr.
In rodents, uricase converts uric acid to allantoin and uricase inhibition raises serum uric acid. Unlike most forms of life, humans lack an active uricase enzyme that converts uric acid to allantoin. Further characterization of potential mechanisms of injury, including increased cyst growth that will be investigated include crystal deposition causing tubular dilatation, increased reactive oxygen radicals and pro-inflammatory cytokines/chemokines causing tubular cell proliferation and endothelial injury are ongoing. In summary, increasing serum uric acid by inhibiting uricase with oxonic acid ("OXO") results in an increase in kidney weight, cyst index, creatinine in PCK rat and RC mouse models of PKD.
Cyst index is increased, suggesting uric acid may act to specifically accelerate disease progression in PKD. Creatinine, supporting the concept of a decrease in filtering capacity of kidneys and. 
Total kidney / body weight ratio – indicating the possibility of accelerated formation or growth of cysts and represents a measure analogous to total kidney volume measures in humans with PKD. Results of this study, in two models of PKD, show similar results and reach similar conclusions, confirming that increasing uric acid by inhibiting uricase enzyme metabolism of uric acid to allantoin, results in substantially and statistically significant increases in: Charles Edelstein and the PKD research team. The abstract presents the findings of studies conducted at the University of Colorado, by Dr. Charles Edelstein of the University of Colorado and Dr. The Abstract "Raising Serum Uric Acid with a Uricase Inhibitor Worsens PKD in Rat and Mouse models" will be presented during the Session Title: Genetic Diseases of the Kidneys, by Dr. The abstract presents new discoveries in two species – mouse and rat models of polycystic kidney disease ("PKD") and reports original work showing the harmful consequence of chronically increased uric acid on both structure and function of kidneys. (" XORTX" or the " Company") XRTX XRTX ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce online availability of the peer-reviewed abstract to be presented Novemat the American Society of Nephrology ("ASN") Annual Conference – Kidney Week. 
25, 2022 (GLOBE NEWSWIRE) - XORTX Therapeutics Inc. Chronically Increased Uric Acid Accelerates StructuralĪnd Functional Changes in Polycystic Kidney Disease.
0 kommentar(er)
